News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

A5 Labs Completes Validation of Its CRO Laboratory Information Management System (LIMS)



11/9/2010 9:16:33 AM

MONTREAL, QUEBEC--(Marketwire - November 09, 2010) - A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) is pleased to announce that the CRO division has completed the validation of its proprietary Laboratory Information Management System (LIMS). The unique custom-made LIMS system will allow A5 Labs' CRO customers to track and receive real-time information on the progress and status of the analysis of their products. The customers will use the Web-based LIMS system to submit requisitions and track the results of the analysis at each stage of the testing as well as purchase copy of the raw data.

"The validation of our LIMS system is a critical step in the start of pharmaceutical CRO business. We anticipate that the LIMS system will significantly increase the productivity of our CRO and will deliver total Quality Assurance to our customers on a timely manner." Said Dr. Richard Azani, President and CEO.

About A5 Labs:

A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.


Contacts:
A5 Laboratories Inc.
Investor Relations
1-877-MIRADOR
info@a5labs.com
www.a5labs.com


Read at BioSpace.com


comments powered by Disqus
A5 Labs
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES